The team

We have gathered a set of skills and experiences that will drive our company to: the forefront of the post-antibiotic age.

The team

We have gathered a set of skills and experiences that will drive our company to: the forefront of the post-antibiotic age.

Leading names and opinion drivers will be brought on board to validate our science. Younger people will be identified and encouraged to join us to create our future. As the leader of the PostABR® class of treatments we will work with people that not only believe in our philosophy but want to grow its influence across medicine.

Leading names and opinion drivers will be brought on board to validate our science. Younger people will be identified and encouraged to join us to create our future. As the leader of the PostABR® class of treatments we will work with people that not only believe in our philosophy but want to grow its influence across medicine.

Founder

Founder

I have long been fascinated by the incredible competency of the human body, and its ability to defend itself against threats. The skin is the first part of our defence system – an amazing organ with multiple functions, including immune competence which extends not only across the skin but also into our mouths, eyes, nose and throat. The immune mechanisms used here form the basis of the Qures platform.

Cometh the hour, cometh the technology.

Nature has the answer:

Chemistry is the key™

Richard G. Stead, Founder: The Qures Group

Today

Today

Richard G. Stead

CEO Qures Group Ltd

Following my Bachelors degree in Chemistry, I spent the next 20 years involved with sales and marketing, particularly to the food and drinks industries and with chemicals, often derived from natural sources, but also with enzymes and hydrogen peroxide. In 1993 I started my first company, a chemical trading and distribution company based upon my experience and contacts in the food area. In 1994 I was one of the founders of a company developing innovative medical devices using natural raw materials, this was subsequently listed in 1997. Since then, I have started and sold several different companies, all linked with chemicals and using my personal experience and technological competence to create unique supply and service aspects for customers, usually with natural resources/technology involved. The latest technology being focussed around nature’s protective skins, such as in citrus peel, and then to human skin. This technology I tried to sell into the UK fresh food industry but price ruled it out. So I designed a new delivery system for a human treatment of pathogens and launched the start of the Qures companies.

Dr Diana Garnham

Chair

After a career that included 10 years as chief executive of the Science Council and 14 years leading the Association of Medical Research Charities, Diana Garnham now has a portfolio career with a focus on strategic leadership, governance and change management. In addition to working as a consultant, she holds several NED positions and serves on a number of national and local advisory bodies in the areas of skills, science and technology.

Following a first degree in politics from the University of Leicester, Diana took an MA in war studies at Kings College and then undertook research at Aberystwyth University into the conduct of WW2 in the Far East. After leaving academic life her career interest developed around how the public relates to advances in science and how the science community responds to and works with the public. She has also worked in key areas of science policy including the use of animals, human embryo research, nuclear weapons, climate change, use of complementary medicine, GM food and patient influence of the research agenda. In 2012 Diana was awarded an Honorary Doctor of Laws by the University of Leicester for her work on the social consequences of science.

Dr Paul R Clayton

Medical

PC graduated from Edinburgh University with a degree in medical pharmacology. He has spent the last 40 years studying the pharmacology of foods and food extracts, and the impact of dietary shift on public health indices.

After serving as a senior scientific officer for the Committee on Safety of Medicines, he worked in science communications for Fleet Street and the BBC, chaired the Forum on Food & Health at the Royal Society of Medicine, and acted as CSO and/or chair of the Scientific Advisory Boards for many companies in the nutrition sector including Biothera (US), Gencor (USA, Hong Kong), Biogenics (Hungary) and others.

He publishes in several areas including omega 3s and their congeners, natural CR-3 agonists, natural BDNF-upregulators, the relationship between TNF-alpha, sex hormones and trauma survival, liver enzyme modulation, and dietary shift and public health.

Dr Kevin Pritchard

Science

Kevin Pritchard graduated from Imperial College with a first class degree in biochemistry and a PhD in neurosciences. He conducted academic research in cardiovascular biochemistry at the National Heart and Lung Institute in London before joining Cambridge Antibody Technology (CaT, then a fledgling biotech company) in 1994. At CaT he was appointed Head of Protein Science – he and his team contributed to numerous therapeutic antibody projects, focusing on inflammation. In 2001 he joined AstraZeneca as Head of Protein Science, working across all therapeutic areas and 10 international research sites. At AZ he held roles in line management, project and portfolio management, and latterly in science policy. While at AZ he was closely aligned with all infectious disease projects and collaborated with leading institutes to investigate treatments for infectious diseases of the developing world. In 2014, Kevin left AZ and established a career as an independent consultant working with biopharmaceutical SMEs. His current interests are primarily in infectious diseases.

Lucy Futter

Ethics/Governance

Following her degree in geography, Lucy has spent most of the career with charitable organisations (including Natural History Museum, Regents Park Zoo and Winchester Cathedral) in administrative and business roles, where she gained insight and experience in corporate governance. At the Science Council she was responsible to the chief executive for relationships with government departments to take forward policies relating to science and its applications. Lucy currently runs The Workstead coworking space in Winchester, of which she was the founder.

Richard G. Stead, CEO Qures Group Ltd

Following my Bachelors degree in Chemistry, I spent the next 20 years involved with sales and marketing, particularly to the food and drinks industries and with chemicals, often derived from natural sources, but also with enzymes and hydrogen peroxide. In 1993 I started my first company, a chemical trading and distribution company based upon my experience and contacts in the food area. In 1994 I was one of the founders of a company developing innovative medical devices using natural raw materials, this was subsequently listed in 1997. Since then, I have started and sold several different companies, all linked with chemicals and using my personal experience and technological competence to create unique supply and service aspects for customers, usually with natural resources/technology involved. The latest technology being focussed around nature’s protective skins, such as in citrus peel, and then to human skin. This technology I tried to sell into the UK fresh food industry but price ruled it out. So I designed a new delivery system for a human treatment of pathogens and launched the start of the Qures companies.

Dr Diana Garnham, Chair

After a career that included 10 years as chief executive of the Science Council and 14 years leading the Association of Medical Research Charities, Diana Garnham now has a portfolio career with a focus on strategic leadership, governance and change management. In addition to working as a consultant, she holds several NED positions and serves on a number of national and local advisory bodies in the areas of skills, science and technology.

Following a first degree in politics from the University of Leicester, Diana took an MA in war studies at Kings College and then undertook research at Aberystwyth University into the conduct of WW2 in the Far East. After leaving academic life her career interest developed around how the public relates to advances in science and how the science community responds to and works with the public. She has also worked in key areas of science policy including the use of animals, human embryo research, nuclear weapons, climate change, use of complementary medicine, GM food and patient influence of the research agenda. In 2012 Diana was awarded an Honorary Doctor of Laws by the University of Leicester for her work on the social consequences of science.

Dr Paul R Clayton, Medical

PC graduated from Edinburgh University with a degree in medical pharmacology. He has spent the last 40 years studying the pharmacology of foods and food extracts, and the impact of dietary shift on public health indices.

After serving as a senior scientific officer for the Committee on Safety of Medicines, he worked in science communications for Fleet Street and the BBC, chaired the Forum on Food & Health at the Royal Society of Medicine, and acted as CSO and/or chair of the Scientific Advisory Boards for many companies in the nutrition sector including Biothera (US), Gencor (USA, Hong Kong), Biogenics (Hungary) and others.

He publishes in several areas including omega 3s and their congeners, natural CR-3 agonists, natural BDNF-upregulators, the relationship between TNF-alpha, sex hormones and trauma survival, liver enzyme modulation, and dietary shift and public health.

Dr Kevin Pritchard, Science

Kevin Pritchard graduated from Imperial College with a first class degree in biochemistry and a PhD in neurosciences. He conducted academic research in cardiovascular biochemistry at the National Heart and Lung Institute in London before joining Cambridge Antibody Technology (CaT, then a fledgling biotech company) in 1994. At CaT he was appointed Head of Protein Science – he and his team contributed to numerous therapeutic antibody projects, focusing on inflammation. In 2001 he joined AstraZeneca as Head of Protein Science, working across all therapeutic areas and 10 international research sites. At AZ he held roles in line management, project and portfolio management, and latterly in science policy. While at AZ he was closely aligned with all infectious disease projects and collaborated with leading institutes to investigate treatments for infectious diseases of the developing world. In 2014, Kevin left AZ and established a career as an independent consultant working with biopharmaceutical SMEs. His current interests are primarily in infectious diseases.

Lucy Futter, Ethics/Governance

Following her degree in geography, Lucy has spent most of the career with charitable organisations (including Natural History Museum, Regents Park Zoo and Winchester Cathedral) in administrative and business roles, where she gained insight and experience in corporate governance. At the Science Council she was responsible to the chief executive for relationships with government departments to take forward policies relating to science and its applications. Lucy currently runs The Workstead coworking space in Winchester, of which she was the founder.